Close
American Drug Delivery & Formulation Summit
Xylem
Industry Reports

Bristol-Myers Squibb to Announce Results for First Quarter 2013 on April 25

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Industry Reports

Study Identifies Tiered Manufacturing in Global Pharmaceutical Markets

A new research project from the Johns Hopkins Bloomberg...
Business & Industry

Structural Pricing Pressure is Reshaping Pharma in 2026

In 2026, global pricing pressure in the pharmaceutical sector has shifted from a temporary, cyclical issue to a structural constraint. Explore how U.S. reforms, European reference pricing, and biosimilar competition are forcing companies to embed pricing risk into core strategy.
Business & Industry

Merck Targets $70B Revenue in 2026 with Cidara Deal

Merck’s roughly $9.2 billion acquisition of Cidara Therapeutics and its $70 billion revenue ambition mark a strategic pivot toward respiratory vaccines and antivirals. Explore how this deal reshapes Merck’s portfolio and signals a broader industry shift toward targeted M&A to offset patent cliffs.
- Advertisement -

Bristol-Myers Squibb Company will announce results for the first quarter of 2013 on Thursday April 25 2013. During a conference call at 10:30 a.m. EDT on April 25 company executives will review financial information and will address inquiries from investors and analysts.

Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com or by dialing 913-312-0650 confirmation code: 1234744. Materials related to the call will be available at the same website prior to the conference call. A replay of the call will be available beginning at 2 p.m. EDT on April 25 through midnight EDT on May 9 2013. The replay will also be available through http://investor.bms.com or by dialing 402-280-9013 confirmation code: 1234744.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover develop and deliver innovative medicines that help patients prevail over serious diseases.

 

 

World Pharma Today brings together the global pharmaceutical industry — from R&D leaders and regulatory affairs professionals to manufacturers and distribution executives — through trusted editorial, market intelligence, and digital engagement.

Our 2026 Media Pack offers integrated solutions to reach your audience:

  • Magazine & Digital Editions Showcase your brand within premium pharmaceutical industry coverage read by executives and decision - makers worldwide.
  • Industry Insights & Reports Align with data - driven analysis, trend reports, and regional roundups across the global pharmaceutical and life sciences value chain.
  • Brand Authority & Credibility Position your company as a thought leader through expert commentary, interviews, and special features.
Download the Media Pack to activate your presence across the global pharma and life sciences ecosystem.

Latest stories

Previous article
A strong cash position of EUR 30.5 million, an annual loss of EUR 6.0 million and significant clinical progress of Adocia projects
Next article
Abbott reports first-quarter 2013 results

Related stories

Industry Reports

Study Identifies Tiered Manufacturing in Global Pharmaceutical Markets

A new research project from the Johns Hopkins Bloomberg...
Business & Industry

Structural Pricing Pressure is Reshaping Pharma in 2026

In 2026, global pricing pressure in the pharmaceutical sector has shifted from a temporary, cyclical issue to a structural constraint. Explore how U.S. reforms, European reference pricing, and biosimilar competition are forcing companies to embed pricing risk into core strategy.
Business & Industry

Merck Targets $70B Revenue in 2026 with Cidara Deal

Merck’s roughly $9.2 billion acquisition of Cidara Therapeutics and its $70 billion revenue ambition mark a strategic pivot toward respiratory vaccines and antivirals. Explore how this deal reshapes Merck’s portfolio and signals a broader industry shift toward targeted M&A to offset patent cliffs.
Business & Industry

U.S. Drug Pricing Reset Becomes Real in 2026

In 2026, U.S. drug pricing finally moved from policy debate to P&L impact. The first set of Medicare “maximum fair prices” and Most‑Favoured‑Nation–style reference pricing are reshaping pharma margins and launch strategies.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

About us

World Pharma Today is a leading Magazine featuring latest industry developments for the Pharmaceutical C-level executives. . . Read More

SUBSCRIBE US

System

RESOURCES

ARCHIVE LINKS

Subscribe

Copyright © 2010-2026 World Pharma Today. All rights reserved. Publication of Leo Marcom Pvt Ltd.

Translate »
MORE STORIES
Poster-style scene with the title 'HOW MODERN WELLNESS RESEARCH IS SHAPING HEALTH INNOVATION' and a glowing meditating figure surrounded by DNA, brain, and heartbeat graphics in a high-tech lab, symbolizing wellness research.

How Modern Wellness Research Is Shaping Health Innovation

Diagram: a few blue cell icons on the left arrowing to a 3x4 grid of blue cells on the right, symbolizing scaling in early-stage cell therapies.

The Starting Material Dilemma: De-Risking Early-Stage CAR-T and Immuno-Oncology Pipelines